Intercept Pharmaceuticals announces new data showing potential of Fixed-Dose Combination of OCA and Bezafibrate to normalize multiple biomarkers in PBC to be featured in podium presentation at EASL Congress June 2023. Read more.
August 21, 2026
No Comments
